MorphoSys Analyst Ratings
MorphoSys Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/15/2023 | 15.91% | Goldman Sachs | $3.5 → $9.25 | Upgrades | Sell → Neutral |
| 06/22/2023 | 87.97% | JMP Securities | → $15 | Reiterates | Market Outperform → Market Outperform |
| 06/16/2023 | 113.03% | Wells Fargo | → $17 | Initiates Coverage On | → Overweight |
| 06/16/2023 | 25.31% | JP Morgan | $3.3 → $10 | Upgrades | Underweight → Overweight |
| 01/03/2023 | — | JP Morgan | Downgrades | Neutral → Underweight | |
| 11/18/2022 | 87.97% | JMP Securities | $32 → $15 | Maintains | Market Outperform |
| 01/14/2022 | — | Morgan Stanley | Downgrades | Overweight → Equal-Weight | |
| 08/06/2021 | — | Deutsche Bank | Downgrades | Buy → Hold | |
| 06/11/2021 | 200.75% | JP Morgan | $32 → $24 | Downgrades | Overweight → Neutral |
| 06/03/2021 | — | Bryan Garnier | Downgrades | Buy → Neutral | |
| 06/03/2021 | — | SVB Leerink | Upgrades | Market Perform → Outperform | |
| 05/24/2021 | 250.88% | Morgan Stanley | → $28 | Upgrades | Equal-Weight → Overweight |
| 03/23/2021 | — | SVB Leerink | Downgrades | Outperform → Market Perform | |
| 11/25/2020 | — | Morgan Stanley | Initiates Coverage On | → Equal-Weight | |
| 11/20/2019 | — | Guggenheim | Initiates Coverage On | → Buy | |
| 11/14/2018 | 326.07% | JP Morgan | $32 → $34 | Maintains | Overweight |
| 11/05/2018 | 376.19% | Piper Sandler | → $38 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023/09/15 | 15.91% | 高盛 | $3.5→$9.25 | 升級 | 賣出→中性 |
| 2023/06/22 | 87.97% | JMP證券 | →$15 | 重申 | 市場表現優於→市場表現 |
| 06/16/2023 | 113.03% | 富國銀行 | →$17 | 開始承保 | →超重 |
| 06/16/2023 | 25.31% | 摩根大通 | $3.3→$10 | 升級 | 減持→超重 |
| 01/03/2023 | - | 摩根大通 | 評級下調 | 中性→減持 | |
| 2022年11月18日 | 87.97% | JMP證券 | $32→$15 | 維護 | 市場表現強於大盤 |
| 2022年01月14日 | - | 摩根士丹利 | 評級下調 | 超重→等重 | |
| 08/06/2021 | - | 德意志銀行 | 評級下調 | 購買→Hold | |
| 2021/11/06 | 200.75% | 摩根大通 | $32→$24 | 評級下調 | 超重→中性 |
| 06/03/2021 | - | 布萊恩·加尼耶 | 評級下調 | 購買→中性 | |
| 06/03/2021 | - | SVB Leerink | 升級 | 市場表現優於→ | |
| 2021/05/24 | 250.88% | 摩根士丹利 | →$28 | 升級 | 等重→超重 |
| 03/23/2021 | - | SVB Leerink | 評級下調 | 跑贏→市場表現 | |
| 11/25/2020 | - | 摩根士丹利 | 開始承保 | →等重 | |
| 2019年11月20日 | - | 古根海姆 | 開始承保 | →購買 | |
| 2018年11月14日 | 326.07% | 摩根大通 | $32→$34 | 維護 | 超重 |
| 2018年11月05日 | 376.19% | 派珀·桑德勒 | →$38 | 開始承保 | →超重 |
What is the target price for MorphoSys (MOR)?
MorPhoSys(MOR)的目標價是多少？
The latest price target for MorphoSys (NASDAQ: MOR) was reported by Goldman Sachs on September 15, 2023. The analyst firm set a price target for $9.25 expecting MOR to rise to within 12 months (a possible 15.91% upside). 6 analyst firms have reported ratings in the last year.
高盛於2023年9月15日報道了MorPhoSys(納斯達克代碼：MOR)的最新目標價。這家分析公司將目標價定為9.25美元，預計MOR將在12個月內上漲至15.91%。6家分析公司在過去一年公佈了評級。
What is the most recent analyst rating for MorphoSys (MOR)?
Morphesys(MOR)的最新分析師評級是多少？
The latest analyst rating for MorphoSys (NASDAQ: MOR) was provided by Goldman Sachs, and MorphoSys upgraded their neutral rating.
納斯達克(Sequoia Capital：MOR)的最新分析師評級由高盛提供，MorPhoSys上調了中性評級。
When is the next analyst rating going to be posted or updated for MorphoSys (MOR)?
MorPhoSys(MOR)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of MorphoSys, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for MorphoSys was filed on September 15, 2023 so you should expect the next rating to be made available sometime around September 15, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查看公開的財務報表，與MorPhoSys的高管和客戶交談，以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。MorPhoSys的上一次評級是在2023年9月15日提交的，所以你應該預計下一次評級將在2024年9月15日左右的某個時候提供。
Is the Analyst Rating MorphoSys (MOR) correct?
分析師對MorPhoSys(MOR)的評級正確嗎？
While ratings are subjective and will change, the latest MorphoSys (MOR) rating was a upgraded with a price target of $3.50 to $9.25. The current price MorphoSys (MOR) is trading at is $7.98, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但MorPhoSys(MOR)的最新評級被上調，目標價從3.50美元上調至9.25美元。MorPhoSys(MOR)目前的交易價格為7.98美元，在分析師的預測範圍內。